We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+9.09%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$5.62B
AUM Growth
+$874M
Cap. Flow
+$401M
Cap. Flow %
7.12%
Top 10 Hldgs %
66.07%
Holding
710
New
128
Increased
146
Reduced
103
Closed
149
Avg Time Held Equity + Options
3.9 quarters
Top 10 Avg Time Held Equity + Options
1.5 quarters
Top 20 Avg Time Held Equity + Options
1.3 quarters
Avg Time Held Equity only
4.1 quarters
Top 10 Avg Time Held Equity only
1.5 quarters
Top 20 Avg Time Held Equity only
1.3 quarters

Top Buys

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$779M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$358M
3
NEWR
New Relic, Inc.
NEWR
+$258M
4
DEN
Denbury Inc.
DEN
+$175M
5
VMW
VMware, Inc
VMW
+$165M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$230M
2
PDCE
PDC Energy, Inc.
PDCE
+$221M
3
UNVR
Univar Solutions Inc.
UNVR
+$219M
4
FOCS
Focus Financial Partners Inc. Class A
FOCS
+$146M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$141M

Sector Composition

Rank Sector Weight
1 Technology 39.86%
2 Healthcare 28.77%
3 Miscellaneous 7.24%
4 Real Estate 5.15%
5 Financials 4.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HPP icon
301
Hudson Pacific Properties
HPP
$622M
$1.13M 0.02%
+24,171
New +$1.04M
2023 Q3
0 quarters
IMUX icon
302
Immunic
IMUX
$92.2M
$1.12M 0.02%
76,169
-3,000
-4% -$57.7K
2022 Q1
6 quarters
CC icon
303
Chemours
CC
$1.95B
$1.11M 0.02%
39,671
-65,400
-62% -$2.25M
2023 Q2
1 quarter
ZURA icon
304
Zura Bio
ZURA
$439M
$1.1M 0.02%
167,167
– –
2023 Q2
1 quarter
IOVA icon
305
Iovance Biotherapeutics
IOVA
$6.5B
$1.1M 0.02%
241,974
-47,410
-16% -$310K
2022 Q1
6 quarters
ADPT icon
306
Adaptive Biotechnologies
ADPT
$4.12B
$1.1M 0.02%
201,340
+1,500
+0.8% +$9.92K
2022 Q1
6 quarters
IRON icon
307
Disc Medicine
IRON
$2.19B
$1.09M 0.02%
23,121
+6,000
+35% +$300K
2023 Q1
2 quarters
MRVL icon
308
Marvell Technology
MRVL
$231B
$1.08M 0.02%
20,000
+5,000
+33% +$295K
2023 Q2
1 quarter
DISH
309
PUT
DELISTED
DISH Network Corp.
DISH
$1.07M 0.02%
126,400
– –
2021 Q2
9 quarters
OCUL icon
310
Ocular Therapeutix
OCUL
$1.59B
$1.07M 0.02%
342,111
+40,000
+13% +$164K
2022 Q1
6 quarters
COTY icon
311
PUT
Coty
COTY
$2.58B
$1.05M 0.02%
+1,418,000
New +$16.7M
2023 Q3
0 quarters
RVNC icon
312
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.02M 0.02%
+88,800
New +$1.71M
2023 Q3
0 quarters
SDGR icon
313
Schrodinger
SDGR
$1.89B
$1.01M 0.02%
35,700
+21,500
+151% +$866K
2022 Q1
6 quarters
ACRV icon
314
Acrivon Therapeutics
ACRV
$74.6M
$1M 0.02%
105,000
+5,000
+5% +$57.8K
2023 Q2
1 quarter
PRAX icon
315
Praxis Precision Medicines
PRAX
$6.78B
$998K 0.02%
38,903
– –
2022 Q1
6 quarters
DYN icon
316
Dyne Therapeutics
DYN
$2.78B
$992K 0.02%
110,752
-65,000
-37% -$700K
2022 Q1
6 quarters
TARS icon
317
Tarsus Pharmaceuticals
TARS
$3.37B
$982K 0.02%
55,262
-48,000
-46% -$849K
2022 Q3
4 quarters
SLN icon
318
Silence Therapeutics
SLN
$565M
$967K 0.02%
98,326
– –
2022 Q2
5 quarters
ACAH
319
DELISTED
Atlantic Coastal Acquisition Corp. Class A Common Stock
ACAH
$965K 0.02%
90,632
– –
2021 Q4
7 quarters
FCPT icon
320
Four Corners Property Trust
FCPT
$2.34B
$960K 0.02%
+43,260
New +$1.09M
2023 Q3
0 quarters
PTCT icon
321
PTC Therapeutics
PTCT
$4.99B
$955K 0.02%
42,601
-2,500
-6% -$93K
2022 Q4
3 quarters
CGEM icon
322
Cullinan Oncology
CGEM
$887M
$950K 0.02%
105,000
+20,000
+24% +$208K
2023 Q2
1 quarter
HYG icon
323
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.8B
$935K 0.02%
+1,400,000
New +$105M
2023 Q3
0 quarters
CRC icon
324
California Resources
CRC
$4.78B
$932K 0.02%
16,648
-356
-2% -$19K
2020 Q4
11 quarters
ATXS icon
325
DELISTED
Astria Therapeutics
ATXS
$925K 0.02%
124,000
+10,000
+9% +$85.3K
2023 Q2
1 quarter
11 12
13
14 15

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q3 2023 Portfolio in Review

As of Q3 2023, UBS O'Connor held 710 positions worth $5.62B, up 18% from $4.75B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

UBS O'Connor deployed $401M of net new capital in Q3 2023, opening 128 new positions and adding to 146 existing holdings. Its largest new stake was Denbury Inc.: 1,931,731 shares worth $189M.

By sector, the portfolio is most concentrated in Technology at 40% of assets, up from 16% a quarter earlier, followed by Healthcare and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $19.7M trimmed.

  • UBS O'Connor's largest Q3 2023 buy was Denbury Inc.: 1,931,731 shares worth $189M.
  • UBS O'Connor added most to Activision Blizzard in Q3 2023, an estimated $779M increase.
  • UBS O'Connor's biggest Q3 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $19.7M.
  • UBS O'Connor fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $230M.
  • UBS O'Connor's ten largest holdings make up 66% of its $5.62B portfolio in Q3 2023.
  • UBS O'Connor opened 128 new positions and closed 149 in Q3 2023.
  • UBS O'Connor's portfolio value rose 18% quarter-over-quarter to $5.62B.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.